NCT06800339 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06800339
Title	A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NEORADJUVANT)
Acronym	NEORADJUVANT
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	University of Maryland, Baltimore
Indications	lung non-small cell carcinoma
Therapies	Carboplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Maryland Proton Treatment Center	RECRUITING	Baltimore	Maryland	21201	United States	Details
University of Maryland Greenebaum Cancer Center	RECRUITING	Baltimore	Maryland	21201	United States	Details
Upper Chesapeake- Kaufman Cancer Center	RECRUITING	Bel Air	Maryland	21014	United States	Details
Baltimore Washington Medical Center- Tate Cancer Center	RECRUITING	Glen Burnie	Maryland	21061	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06800339Clinical Trial Detail